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| BACKGROUND
The management of urological cancers encompasses five different cancer sites-kidney, bladder, prostate, testis and penis. Presentation and management of these cancers are very different. The association of lymphoedema with bladder, prostate, testicular and penile cancer, either as a consequence of treatment or progressive disease is well recognized. It may be that since these cancers are also commonly associated with urinary and sexual dysfunctions the issue of lymphoedema is not considered during follow-up, more research is needed.
The role of the Clinical Nurse Specialist (CNS) in urology is complex and varied. The clinical focus for some is entirely cancer-related, for others it is non-cancer conditions, while others span multiple pathologies. 1, 2 Further, whereas some specialist nurses are cancer-site specific, for example, breast cancer, this is not the case for most urooncology CNS roles. 3 The CNS role is essential within the multidisciplinary team (MDT), supporting patient information and enabling shared decision-making at every stage of the cancer journey. 2, 4 The information-giving aspect is significant to the patient experience and understanding of the disease. 3 Whilst patient contact with a cancer CNS in England may have increased, studies show worrying regional variances. 3 With increased workload pressures "meeting information needs" is often reported as being left incomplete. 3 Men with prostate cancer, for example, were found to have continued information needs years after diagnosis. 5 Changing national demographics and increased survival are likely to increase patient numbers and complexity. In this context, priority of attention in daily clinics and in continuous professional development (CPD) is rationally given to conditions of perceived or known risk to mortality or morbidity. However, lower profile conditions like lymphoedema may be overlooked.
Lymphoedema can be congenital or acquired, and may present at any part of the cancer continuum. 6, 7 The characteristic of swelling (oedema) in the genitals and/or legs and dull ache/discomfort, in absence of other causes (such as thrombosis, pharmaceutical vasodilator or infection), may be the presenting symptom. 8, 9 Lymphoedema can be an early post-operative sequela, 10 a longer-term consequence of treatment 11, 12 or a progressive sign at a palliative care stage.
9,13
The symptoms of lymphoedema can be debilitating; excessive swelling of the genitals can hinder sexual activity and urination, affect sitting, walking and dressing and be emotionally disabling. 14, 15 Ongoing physiological changes cause increased risk of infection, further lymphatic vessel damage and disfigurement. 16 Identification and treatment by specialist services has been shown to reduce morbidity and complications. 17, 18 Research on genitourinary cancer-related lymphoedema is sparse compared to breast cancer-related. 11, 19 A systematic review and meta-analysis reported lymphoedema incidence of 21% in penile cancer, 16% bladder cancer and 4% in prostate cancer cases 11 ; however, these figures were based on very small studies. Cancer treatment techniques have continued to improve, but whether this has reduced incidence or, with increased survivorship increased it, remains unknown.
The lack of understanding of the experiences of men with lymphoedema post-genitourinary cancer led to the development of the Lymphoedema Genitourinary Cancer Questionnaire (LGUCQ).
20
A collaborative development between uro-oncology, lymphoedema specialists and male patients (both with and without lymphoedema) initiated a simple two-sided tool aimed to facilitate self-reporting of symptoms and difficulties associated with lymphoedema. Related pilot work suggests that written self-report tools enable men to disclose more sensitive information than they would verbally. 21 However, the LGUCQ had not been formally evaluated in an urooncology department to identify the benefits (or not) from the perspective of the patients and health professionals (urology and lymphoedema). Thus, the following research questions derived from the research literature.
2 | RESEARCH QUESTIONS 
WHAT IS KNOWN ABOUT THIS TOPIC
• Association of lymphoedema with four of the five urological cancer sites (bladder, prostate, testicular and penile cancer), either as a consequence of treatment or progressive disease is well recognized.
• However, as these cancers are also commonly associated with urinary and sexual dysfunctions, the issue of lymphoedema is generally unrecognized during follow-up.
• Little research has been published into the impact of providing a self-report tool for lymphoedema, such as the LGUCQ, to genitourinary cancer patients.
WHAT THIS PAPER ADDS
• This paper adds some understanding to the current gap in the literature surrounding genitourinary lymphoedema.
• This research found that giving patients undergoing genitourinary cancer treatment the opportunity to complete the LGUCQ may be a prompt and catalyst for enabling difficult conversations.
• The paper also suggests that health professionals may need additional training in genital oedema to accurately identify and feel more confident in addressing this issue with genitourinary cancer patients.
Ultimately, interviews took place with eight participants from two health boards: three patients, three lymphoedema practitioners and only two urology health professionals due to staff availability.
| DATA ANALYSIS
Qualitative interview data was analysed using a thematic framework approach based on the research questions, initially by the primary researcher and then by the second researcher. Any disagreement would be taken to a third member of the team. All research team members were HCPs in urology or lymphoedema. Initial coding of the data was carried out to identify similarities in words and phrasing; subsequent analysis allowed identification of and categorisation of emerging themes within the framework. Further review and discussion of differing interpretation allowed robust conclusions to be drawn. The results of the analysis were then compared against a wider literature on the use of tools for symptom disclosure for a greater conceptual understanding of the issues.
| FINDINGS
Findings are reported in relation to five pragmatic themes:
• perceived barriers to symptom disclosure and information sharing
• the LGUCQ as facilitator of disclosure of lymphoedema symptoms
• the LGUCQ as useful and pragmatic addition to the patient pathway
• support needed by patients in completing the LGUCQ, or by the health professionals in its administration
• refinements required to the tool, or the process of administration, before wider roll out.
| Barriers to symptom disclosure and information sharing
At times, the ability to speak openly about symptoms of genital oedema was problematic to both the male patients and the health professionals irrespective if they were male or female. The relational nature of the consultation meant that separating out whether factors were patient or professional may be somewhat unrealistic, but was completed for the purposes of analytical discussion.
Patient quotations are indicated with a P, urology health professionals with HCP and lymphoedema practitioners with lymphoedema practitioner (LP).
| Approach to the consultation
Patients described a frank, matter-of-fact manner from the professional and themselves as useful, and affect disclosure of symptoms and information sharing.
They were talking about it matter-of-fact to me, and you know, that was fine as far as I was concerned. That brought it out of me… that made me carry on… (P03)
However, there was intimation that this openness was contextual and felt to be a necessity of the situation for patients.
I can understand why some men wouldn't say about the problem …the private part area is something that men perhaps generally don't want to talk about… I perhaps wouldn't talk about it normally, but now I've got a problem with it, I have to talk about it.
Otherwise people won't understand my problem. (PO2) There was recognition that symptom-specific prompts may be required, but there was an expectation by the HCP that if men had swelling this would be reported. 
| Lack of risk awareness and surveillance for lymphoedema
A barrier to early disclosure of lymphoedema symptoms was that the patients were not made aware that they were at risk of lymphoedema and that surveillance for the condition from health professionals was variable. The lack of information on risk led to some men to describe their symptoms of lymphoedema as a shock. The variation in levels of surveillance from health professionals was also acknowledged by a HCP participant who recognized that genital oedema was going unrecognized, even within the same hospital or department.
…I know that there is a variation …that there is a lack of awareness, even in the hospital really. When you see patients from another speciality …and you think well hang on a minute there is [lymphoedema] , …not all patients are referred…to lymphoedema, they just accept that "ok your leg is swollen probably because of cancer, but that's it, put up with it." (HCP4)
| Subject avoidance on both sides
Linked to the enabling effect of specific questions, or prompts, was the timing of enquiry regarding genital oedema, and whether it was the patient or the health professional who delayed broaching the subject. All the lymphoedema practitioners interviewed explained that the subject of genital oedema might not be addressed on the patient's first visit and focus would turn to leg oedema if present; the main reason given was a perception of patient shyness. There was some recognition that a more pro-active approach may be required but the delay in addressing the topic of genital oedema was mostly described as a conscious decision on the part of the professional.
…maybe we need to be a bit more pro-active…if I feel the patient doesn't want to talk at that first visit I would leave it until the second visit, and maybe introduce again, being more pro-active in trying to get them to talk about genital or scrotal oedema. (LP2)
A lymphoedema practitioner (LP3) recognized that a reluctance to discuss genital problems may come from either the patient or the professionals. She described how several variables affected the timing and content of the conversation at a first assessment. This included the age of the patient relative to herself, and whether the man was accompanied. Whilst the same lymphoedema practitioner mooted that the gender of the professional in the consultation might also be a factor for men, this was not identified as an issue by the patients interviewed.
One patient (P02) acknowledged a lack of disclosure of genital symptoms but still complained of a delay in his professionals addressing the issue. He suggested that the health professionals were lacking either the experience or the desire to deal with the issue. This may suggest that an additional factor in timely identification of lymphoedema is the training and experience of the health professional to know who is at risk, and that patients may not self-report without direct questioning. 6.2 | The LGUCQ as a tool for facilitating disclosure 6.2.1 | A catalyst giving men a voice, symptom validity and control
The LGUCQ self-report tool was described as a "catalyst," which "trig- 
| Summary of findings in relation to the second theme
The findings support the LGUCQ as a tool, which can act as a catalyst to facilitate disclosure of symptoms of genital oedema through the specificity of the questions. The tool was reported to enable useful conversation and greater disclosure. In addition, both patients and HCP valued the creation of the patient's own written record of the impact of the symptoms, at a given time.
| The LGUCQ as a useful addition to the male genitourinary cancer patient pathway
All the patients interviewed stated that the questionnaire was acceptable to them. One man (P01) who had already become well informed about lymphoedema reported initially feeling he was completing the
LGUCQ for someone else rather than for his own benefit; despite this, he later described it as an "essential" addition to the care pathway.
Patients and health professionals expressed that the LGUCQ self-report tool would add value to the patient care pathway. The reasons given were both practical and psychological.
| A normalizing effect for men
The effect of having a questionnaire directed at their particular issues led one patient (P02) to describe it as a "fantastic thing" and how "reassuring" it was "that somebody is actually looking at this and actually asking the questions…." Another (P01) felt so strongly about the pertinence of the tool that they added further comment to their transcribed interview, suggesting that it might make men feel less alone in their suffering.
I think your questionnaire is essential for male patients following surgery in case they develop lymphoedema; 
| Better use of time and resources by generating quality information
A urology-based HCP1 pointed out that lymphoedema was not their speciality therefore the specificity of the questions provided a useful aide memoire in the busy outpatient/clinical context. The same HCP pointed out that, in addition to the utility of the LGUCQ for gathering appropriate information, it could save time and resources by doubling as a referral document to specialist lymphoedema services. For the lymphoedema specialists, the LGUCQ was suggested to be a useful supplement to standard lymphoedema assessment documentation. Earlier disclosure of issues related to genital oedema, including psychological problems, was noted to be a product of the use of the LGUCQ.
| Facilitating parity with other long-term effects of cancer treatment
Urology-based health care professional (HCP4) identified the LGUCQ as useful in raising the awareness among other health professionals to the risk of lymphoedema for some men and the existence of specialist services for onward referral. In addition, that when patients were aware of their condition, and of the existence of specialist services, they could help drive their own care. This was compared to the commonly acknowledged possibility of impotence and incontinence as consequences of genitourinary cancer and its treatment.
| Summary of findings in relation the third theme
The findings support the LGUCQ as a useful and pragmatic addition to the pathway of care of men with genitourinary cancer. The LGUCQ was acceptable to patients, helped normalize their situation and was anticipated to reduce the sense of being feeling alone in the experience. HCPs reported the use of LGUCQ led to better use of time and resources through generating timely and better-quality information.
Finally, it was recognized as having the potential to raise awareness among other health professionals and patients to bring parity of care with other long-term effects of genitourinary cancer.
| Support needed by HCP and patients to use the LGUCQ
During the study, patients were given time to complete the LGUCQ in a clinic with a health professional nearby. This was the preferred setting for most participants. At interview, the patients reported that they had not needed support to complete the tool but would welcome greater opportunity to discuss any issues raised, for example, P02; this was confirmed by the health professionals. One lymphoedema practitioner (LP1) felt that it would be better to send the LGUCQ out before the appointment, so the patient would have time to think about the questions before attending. The lymphoedema practitioners interviewed were very experienced and reported needing no support but they anticipated that younger colleagues, or those with less experience, might need further training/support to deal with the questions or emotions raised.
| Summary of findings in relation to the fourth theme
Patients completing the LGUCQ in a clinic environment needed very little support in completing the LGUCQ but wanted time to discuss any issues raised. HCPs in urology suggested specific launch information being available when the LGUCQ came into wider practice and visual prompts such as posters on which patients are at risk of lymphoedema. Lymphoedema practitioners felt younger or newer colleagues may need further training or support to deal with the patient issues raised by the LGUCQ.
6.5 | Refinements required to the tool, or the process of administration, before wider roll out
The findings suggested that LGUCQ was well received overall, as was the process of giving it to patients in urology outpatient clinics when they fulfilled the criteria of being at-risk of lymphoedema.
[ Some suggestions for change were made by patient and health professional participants, but none of these were unanimous. These included the location of being given the self-report tool, having more space to write an explanation of symptoms or impact, and as indicated in the previous section, having more time to discuss the highlighted problems in clinic.
In relation to the location of patients being given the LGUCQ, one patient (P01) suggested that the LGUCQ (and details of their nearest lymphoedema clinic) should be in the discharge pack of the surgical ward for men within the lymphoedema-risk criteria. However, in self-contradiction, he added that "…some patients will be shy or reluctant to complete the questionnaire, so it could be completed with a professional clinician who will be able to interpret the questions if need be" (P01). Similarly, another patient (P02) and some health professionals thought men should have time to consider the questions for a while before attending clinic. However, both the patient and professionals suggested that patients may then not complete it at all or may forget to bring it with them.
One lymphoedema practitioner (LP03) suggested the LGUCQ could be repeated at review appointments to help map progress or report change of symptoms, so that treatment continues to be patient value-based.
The suggestion of having a digital online completion version of the LGUCQ was acknowledged as being potentially useful but all the patient participants in this study stated a preference for the paper version.
| Summary of findings in relation to the fifth theme
The LGUCQ was well received by patients and health professionals. It was important to patients and health professionals that patients had time to consider the questions and to discuss any issues raised, but whether the LGUCQ should be completed at home or in a clinic was not clearly established. The potential of the LGUCQ as an ongoing monitoring tool and the relative benefits of paper and digital versions of the LGUCQ were raised and would need further research.
| DISCUSSION
This study had two implicit assumptions, first that there were barriers to the identification of lymphoedema in uro-oncology clinics, second that enabling patient identification of symptoms might overcome such barriers and lead to early, appropriate onward referral.
The increased recognition of a "risk of lymphoedema" as a consequence of some cancer treatments has not been seen in relation to genitourinary cancers as it has in breast cancer care. Consequently, the gap widens between these cancer sites in terms of lymphoedemarelated research and evidence to guide practice. Incidence and prevalence figures for genital oedema remain sparse and identification of those at risk of genitourinary cancer-related lymphoedema is largely theoretical. Large-scale sharing of data has the potential to improve knowledge of genitourinary cancer-related lymphoedema as it has done for penile cancer. 9 In the absence of specific audited standards or clinical guidelines, and given the complexity and size of urology CNS caseload, 1, 3 it is unlikely that the CNS will initiate a discussion with the patient regarding genital oedema or lymphoedema. It may be that the onus should be on the patients to report troubling symptoms. However, a limiting factor would be that some men, particularly older men, have been found to be reluctant to discuss and disclose problems of a genital nature, affecting their initial health-seeking behaviours. 22, 23 Whilst a pilot study by Sampuro et al 21 found that men with prostate cancer were able to disclose more sensitive information in written than verbal form, this study indicated that using a tool which had patient generated images and vocabulary, the LGUCQ, enabled earlier and more accurate disclosure and helped normalize the experience.
Using objects as tools to enable difficult conversations is a technique common to work with children, 24 adults after trauma 25 and with vulnerable adults. 26 The potential of a co-produced questionnaire to act as a conversation catalyst was the basis for this study and the findings confirmed this premise.
The study was successful in achieving its objectives in terms of establishing the usefulness of the LGUCQ as a pragmatic addition to the genitourinary cancer care pathway for men at risk of lymphoedema. This was found to be possible without further refinement of the LGUCQ, on the proviso that in terms of support, patients were given the time to discuss any issues disclosed with a health professional who was well-informed in relation to lymphoedema. The findings suggest that some younger or less experienced lymphoedema practitioners might need training, specific to urology and genital oedema problems, in order to feel confident in addressing patient concerns. Given the size and scope of this study, this finding requires further research.
A suggested development of the LGUCQ was a non-cancer version. Lymphoedema practitioners raised that there are men who attend lymphoedema services with non-cancer-related genital lymphoedema therefore omitting the word "cancer" would be useful for this wider group of men. The frequency of occurrence is thought to be as many as 10% of men with bilateral leg oedema. 27 There is currently no standard protocol to assess the presence of genital oedema in this patient population, further research is needed.
In contrast to evidence reviews in relation to initial health seeking behaviours of men 22, 23 this study did not find gender differences to disclosure; the men reported being just as likely to disclose symptoms LGUCQ indicated potential service efficiency by addressing issues earlier in a series of consultations and in recognizing when onward referral might be appropriate, for example, to psychological support.
For staff in urology clinics, lymphoedema was recognized as only one of a very large number of issues that they may need to address with this group of patients at review, so the simple but specific questions on the two-sided LGUCQ was appreciated. A limitation of this study was that, without local mandate, such as a clinical standard to identify men at risk of lymphoedema hence prompting the use of the LGUCQ, the busy daily pressures of the urology review clinics often drowned out the study. Setting such a standard and auditing against it with the
LGUCQ could further establish its utility to both patients and urology professionals.
Further practical limitations on the study emerged from the current pressures on all UK health services. Over the period of the study several staffing issues occurred which were outside the control of the research team. One consultant withdrew due to overwhelming work demands and two CNS changed their posts. These meant that recruitment of patients to the study was frequently broken. Ultimately only two of the three health boards participated.
Despite being a small study, the LGUCQ self-report tool for men was found to be a pragmatic and useful addition to the patient care pathway for a specific and identifiable group of men at risk of lymphoedema. Implementation into regular practice would require very little change to practice, or the tool itself, and the benefits of earlier, appropriate management of symptoms would benefit patients and health service in terms of reduced morbidity. The limited size of the study is acknowledged as a limitation in terms of making wider generalizations but in terms of the research objective to show the pragmatic utility of the LGUCQ self-report tool, the study was successful. Further, that if clinical standards were set this narrow criteria of men after genitourinary cancer that is, those with lymph node or bladder wall involvement, the next stage could feasibly be a urology-based clinical audit, rather than a scaling up of this specific study.
| CONCLUSIONS AND IMPLICATIONS FOR PRACTICE
The findings of this study suggest that the inclusion of the LGUCQ selfreport tool within uro-oncology clinics could improve patient outcomes by the earlier identification of lymphoedema. This albeit small study, found issues which limited the identification of lymphoedema within uro-oncology services from health professionals regardless of gender.
The findings also suggested that younger or less experienced lymphoedema practitioners may need additional training in order to feel confident in addressing these issues with patients. Thus, placing the onus on patients to identify problems through the LGUCQ may increase a more prompt and accurate disclosure as well as normalizing the experience.
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